Table 4.
Association Between the Change of ER, PR, and Her-2 Status and Clinicopathological Variables
| Feature | No Change | Change | Change in Any Receptor | ER Discordance P value | PR Discordance P value | HER2 Discordance P value | |
|---|---|---|---|---|---|---|---|
| Chi-Square p value | |||||||
| T-stage(n=242) | 5.778 | 0.216 | 0.728 | 0.106 | 0.746 | ||
| pT1 | 25(10.3) | 29(12.9) | 12(5.0) | 19(7.8) | 5(2.1) | ||
| pT2 | 39(16.1) | 60(24.8) | 27(11.2) | 44(18.2) | 15(6.2) | ||
| pT3 | 6(2.5) | 18(7.4) | 4(1.6) | 13(5.4) | 4(1.6) | ||
| pT4 | 6(2.5) | 3(1.2) | 2(0.8) | 1(0.4) | 0(0) | ||
| pTx | 24(9.9) | 32(13.2) | 11(4.5) | 25(10.3) | 6(2.5) | ||
| N-stage(n=242) | 4.325 | 0.363 | 0.170 | 0.922 | 0.974 | ||
| pN1 | 24(9.9) | 23(9.5) | 7(2.9) | 18(7.4) | 7(2.9) | ||
| pN2 | 17(7.0) | 32(13.2) | 17(7.0) | 22(9.1) | 7(2.9) | ||
| pN3 | 22(9.1) | 41(16.9) | 16(6.6) | 30(12.4) | 7(2.9) | ||
| pN4 | 6(2.5) | 6(2.5) | 1(0.4) | 5(2.1) | 1(0.4) | ||
| pNx | 31(12.8) | 40(16.5) | 15(6.2) | 27(11.2) | 9(3.7) | ||
| M-stage(n=242) | 2.213 | 0.331 | 0.749 | 0.720 | 0.912 | ||
| pM0 | 95(39.3) | 138(57.0) | 54(22.3) | 98(40.5) | 30(12.4) | ||
| pM1 | 5(2.1) | 3(1.2) | 2(0.8) | 3(1.2) | 1(0.4) | ||
| pMx | 0(0) | 1(0.4) | 0(0) | 1(0.4) | 0(0) | ||
| Surgery(n=242) | 0.324 | 0.569 | 0.278 | 0.776 | 0.806 | ||
| Yes | 95(39.3) | 137(56.6) | 55(22.7) | 97(40.1) | 28(11.6) | ||
| Not | 5(2.1) | 5(2.1) | 1(0.4) | 5(2.1) | 3(1.2) | ||
| Radiotherapy(n=242) | 0.248 | 0.618 | 0.331 | 0.164 | 0.886 | ||
| Yes | 66(27.3) | 39(16.1) | 26(10.7) | 47(19.4) | 13(5.4) | ||
| No | 91(37.6) | 47(19.4) | 30(12.4) | 55(22.7) | 18(7.4) | ||
| Chemotherapy(n=242) | 5.481 | 0.0192 | 0.031 | 0.259 | 0.258 | ||
| Yes | 125(51.6) | 90(37.2) | 51(21.1) | 88(36.4) | 29(12.0) | ||
| No | 22(9.1) | 5(2.1) | 4(1.6) | 14(5.8) | 2(0.8) | ||
| Endocrine therapy(n=242) | 3.9 | 0.048 | 0.877 | 0.002 | 0.850 | ||
| Yes | 55(22.7) | 61(25.2) | 30(12.4) | 65(26.9) | 16(6.6) | ||
| No | 44(18.2) | 82(33.9) | 27(11.2) | 36(14.9) | 15(6.2) | ||
| Trastuzumab therapy(n=242) | 3.212 | 0.073 | 0.331 | 0.171 | 0.366 | ||
| Yes | 7(2.9) | 3(1.2) | 1(0.4) | 2(0.8) | 2(0.8) | ||
| No | 96(39.7) | 136(56.2) | 55(22.7) | 100(41.3) | 29(12.0) | ||
| Auxiliary endocrine therapy(n=242) | 4.55 | 0.336 | 0.624 | 0.071 | 0.776 | ||
| Untreated | 55(22.7) | 60(24.8) | 27(11.2) | 36(14.9) | 15(6.2) | ||
| Tamoxifen | 29(12.0) | 53(21.9) | 21(8.7) | 43(17.8) | 10(4.1) | ||
| AI ± GnRH | 11(4.5) | 21(8.7) | 8(3.3) | 15(6.2) | 2(0.8) | ||
| TAM + GnRH | 3(1.2) | 4(1.6) | 0(0) | 4(1.7) | 1(0.4) | ||
| AI + TAM ± GnRH | 1(0.4) | 4(1.6) | 0(0) | 3(1.2) | 1(0.4) | ||
| GnRH mono | 1(0.4) | 0(0) | 0(0) | 0(0) | 0(0) | ||
| Metastasis | 0.853 | 0.653 | 0.189 | 0.136 | 0.390 | ||
| Lymph nodes and bone | 49(20.2) | 74(30.6) | 31(12.8) | 53(21.9) | 14(5.8) | ||
| Viscus | 49(20.2) | 63(26.0) | 22(9.1) | 44(18.2) | 17(7.0) | ||
| Brain | 2(0.83) | 5(2.1) | 3(1.2) | 4(1.7) | 1(0.4) | ||
| Different lines of ET(n=86) | 51.76 | 0.0001 | |||||
| 0 | 80(93.0) | 6(7.0) | |||||
| 1 | 42(17.3) | 44(18.1) | |||||
| 2 | 70(28.9) | 16(6.6) | |||||
| 3 | 77(31.8) | 9(3.7) | |||||
| 4 | 80(33.0) | 6(2.5) | |||||
| 5 | 85(35.1) | 1(0.4) | |||||
| 6 | 84(34.7) | 2(0.8) | |||||
| 7 | 84(34.7) | 2(0.8) | |||||
Notes: Correlations between several diagnostic factors or adjuvant therapies and the occurrence of receptor changes were analyzed. Data was not fully (n = 270 = 100%) available for each factor but percentage according to n=242 = 100% is displayed in brackets (Twenty-eight patients were unable to determine whether hormonal receptor changes occurred because of the uncertain state of Her2 at metastasis sites, so exclude).
Abbreviations: T, primary tumor size; N, regional lymph node; M, distant metastasis, pT, pathological tumor; pN, pathological node; pM, pathological metastasis. ATM, Tamoxifen; AI, Aromatase inhibitor.